Evaluate XERS stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in XERS? | Glauxie AI

Q: What are the risks of investing in XERS?

Xeris Biopharma Holdings, Inc. (XERS) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO John Shannon. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company... Employees: 435.

Q: How much debt does XERS have?

Review XERS total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is XERS a good long-term investment?

Evaluate XERS as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in XERS?

🦉

Xeris Biopharma Holdings, Inc. (XERS)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOJohn Shannon

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and...

Key Executives

Name	Title
Allison Wey	Senior Vice President of Investor Relations & Corporate Communications
Anh Nguyen	Chief Medical Officer
Beth Hecht	Chief Legal Officer & Corporate Secretary
Brian Conner	SVP of Quality and Chief Compliance & Risk Officer
John Shannon	Chief Executive Officer & Director
Kendal Korte	Senior Vice President of Human Resources

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

XERS Profile Financials

Is XERS stock safe? How much debt does XERS have? Is XERS a good long-term investment?